Singular Medical’s Silü® ICM Secures NMPA Approval, Marking China’s First Domestic Breakthrough in ICM
Listed below are overseas competing products
inkMacSystemFont, "Helvetica Neue", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; letter-spacing: 0.544px; white-space: normal; background-color: rgb(25, 25, 25); user-select: auto;"/>
Listed below are overseas competing products
Recurrent unexplained syncope and transient loss of consciousness
Cryptogenic ischemic stroke, screening for occult paroxysmal atrial fibrillation
Paroxysmal palpitations with suspected arrhythmia that cannot be confirmed via short-term examinations
Long-term monitoring for postoperative atrial fibrillation recurrence, and cardiac screening for high-risk populations with malignant arrhythmias
Long-term evaluation of bradyarrhythmias such as long pauses and conduction blocks
Founded in 2017 and headquartered in Suzhou, Singular Medical (“Singular”) focuses on the fields of arrhythmia and heart failure. The company has developed and is developing a full lineup of products covering cardiac screening, rhythm monitoring, remote follow-up systems, the Singular Cloud Platform, electrocardiogram recorders, cardiac pacemakers, implantable cardioverter-defibrillators (ICDs), and various pacing/defibrillation leads for screening, diagnosis, treatment and monitoring workflows. Its business portfolio spans implantable devices, digital healthcare and artificial intelligence technologies.
